Colorectal cancer: which progress in next years?;Cancers colorectaux: Quels progrès attendus à court terme?

Revue du Praticien

Volumn 60, Issue 8, 2010, Pages 1111-1115

  Bachet, Jean Baptiste ^a   Rougier, Philippe ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EVEROLIMUS; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; TEMSIROLIMUS;

CANCER SCREENING; COLORECTAL CANCER; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; HIGH RISK POPULATION; HUMAN; MOLECULAR BIOLOGY; OCCULT BLOOD TEST; PHARMACOGENETICS; PRESCRIPTION; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FORECASTING; HUMANS; MASS SCREENING;

EID: 78149236063     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-60.
2. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-74.
3. Sargent DJ, Marsoni S, Thibodeau SN, et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol 2008;26:4008.
4. Buecher B, Laurent-Puig P. Colectomie préventive dans le cancer du côlon héréditaire. Rev Prat 2008;58:1281-5.
5. Pagès F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009;27:5944-51.
6. Kerr D, Gray R, Quirke P, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009;27:4000.
7. Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010;11:241-8.
8. Prise en charge thérapeutique des métastases hépatiques des cancers colorectaux. Recommandations pour la pratique clinique. Gastroenterol Clin Biol 2003;27:B7-104.
9. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-16.
10. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009;27:1829-35.
11. Riquet M, Foucault C, Cazes A, et al. Pulmonary resection for metastases of colorectal adenocarcinoma. Ann Thorac Surg 2010;89:375-80.
12. Ellas D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63-8.
13. Bolge V, Mendiboure J, Pignon JP, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 2010;28:2556-64.
14. Kim JG, Chae YS, Sohn SK, et al. IVS10+12A>G polymorphism in hMSH2 gene associated with prognosis for patients with colorectal cancer. Ann Oncol 2010;21:525-9.
15. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatc colon cancer. J Clin Oncol 2009;27:5924-30.
16. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009;27:5727-33.
17. Thésaurus national de cancérologie digestive www.tncd.org;
18. Fédération française de cancérologie digestive. Recommandations. www.ffcd.fr